Nang Kuang Pharmaceutical Co., Ltd. announced that The Abbreviated New Drug Application (ANDA) for Icatibant Injection, 30 mg per 3 mL (10 mg/mL) Prefilled Syringe indicated for the treatment of hereditary angioedema (HAE) has been final approved by the U.S. Food and Drug Administration (FDA).